A clinical overview of the Climara (estradiol transdermal) shortage for healthcare providers. Includes supply status, therapeutic alternatives, and patient management strategies.
Climara (estradiol transdermal system, Bayer HealthCare Pharmaceuticals) has experienced intermittent supply disruptions affecting pharmacies nationwide. As a once-weekly estradiol patch available in six strengths (0.025 mg/day through 0.1 mg/day), Climara is a cornerstone of transdermal hormone replacement therapy for many patients. This article provides prescribers with a current overview of the supply situation, therapeutic alternatives, and clinical considerations for patient management during the shortage.
As of February 2026, Climara continues to face availability challenges at retail pharmacies. The shortage is not consistently reflected on the FDA Drug Shortage Database, which relies on manufacturer-reported data. However, the clinical reality — confirmed by pharmacist reports and patient feedback — is that certain strengths, particularly the 0.05 mg/day and 0.075 mg/day doses, remain difficult to source in many markets.
The underlying causes include:
Interruptions in estradiol therapy can result in rapid recurrence of vasomotor symptoms, with patients reporting return of hot flashes and night sweats within 48 to 72 hours of a missed dose. For patients using Climara for osteoporosis prevention, sustained gaps in therapy may compromise bone mineral density maintenance.
Additionally, patients who have been stable on a specific Climara strength may experience symptom variability if switched to a different formulation or delivery system, necessitating monitoring and potential dose adjustment.
When Climara is unavailable, the following therapeutically equivalent or clinically appropriate alternatives should be considered:
AB-rated generic estradiol transdermal patches are the most direct substitution. Multiple manufacturers (Mylan, Noven, others) produce generic weekly and twice-weekly patches. Pharmacists can substitute generics for Climara unless the prescription specifies "dispense as written." Generic patches typically cost patients $25 to $60 per box of 4 patches versus $130 to $200 for brand-name Climara.
When converting from a weekly patch to a twice-weekly patch, the daily delivery rate remains the primary dosing parameter. A patient on Climara 0.05 mg/day should be transitioned to a twice-weekly patch delivering 0.05 mg/day.
Transdermal gels and sprays maintain the benefit of avoiding first-pass hepatic metabolism, which may be relevant for patients at elevated thrombotic risk.
Oral estradiol (0.5 mg, 1 mg, 2 mg tablets) is the most widely available and affordable option, with costs as low as $4 to $15 per month. However, oral administration involves first-pass hepatic metabolism, which may increase hepatic protein synthesis (including clotting factors) and carries a potentially higher venous thromboembolism risk relative to transdermal delivery. This should be weighed in the clinical context, particularly for patients with obesity, thrombophilia history, or advanced age.
Switching products during a shortage can create cost confusion for patients. Key points to communicate:
For comprehensive cost information, see our provider's guide to helping patients save on Climara.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
